Researchers have created and demonstrated the ability of fish-shaped microrobots, that are pH-responsive, to deliver chemotherapy drugs to cancer cells.
Thanks to funds raised by you – the Movember community – researchers have discovered the world’s first precision medicine for prostate cancer. This is how it works. To discover more about the hair-raising impact of your fundraising and donations, head to https://movember.com/impact.
Dr. Mark Scholz is a medical oncologist specializing exclusively in the management and treatment of prostate cancer patients. In this episode of “Answering YouTube Comments,” he explains why it is beneficial to screen asymptotic men for prostate cancer and whether body scans are useful for men on active surveillance. 0:05 What percentage of dangerous prostate cancers are asymptomatic? I feel like testing asymptomatic men does more harm than good 1:36 I have a PSA under 6.0 and Gleason 6. Other than mpMRI, are any other scans necessary. Of course, anyone on active surveillance who starts having hip pain is going to expect the worse. Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org To learn more about prostate cancer visit http://www.pcri.org Who we are:The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.The information on the Prostate Cancer Research Institute’s YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.#ProstateCancer #Prostate #MarkScholzMD
Neeraj Agarwal, MD, summarizes results from the TITAN trial of apalutamide in mCSPC, focusing on patient-reported quality of life outcomes.
Little Black Book, Dan Sparkes, creative director at Bullfrog and Pam Kleemann-Passi, Melbourne based visual artist, spoke to LBBs Zoe Antonov about the process behind creating a suit made entirely of human moustache hair
Phillip J. Koo, MD, Division Chief of Diagnostic Imaging and Northwest Region Oncology Physician Executive at the Banner MD Anderson Cancer Center in Phoenix, Arizona, reviews the fifth session of the 31st International Prostate Cancer Update which he moderated and which focused on next-generation imaging, specifically PSMA. To view the videos from this collection, visit https://grandroundsinurology.com/international-prostate-cancer-update-2021-session-review-next-generation-imaging-focus-on-psma/
Horizon Conference Management organized a webinar “New Age Management of Prostate Cancer” under the aegis of “Cancer Research And Statistic Foundation”.Date: 13 November 2021Time: 06:30 PM ISTSession: New Age Management of Prostate CancerView and Download Agenda:https://drive.google.com/file/d/1AuZbyz9VDqK7F9ziOoeMG2rMewjW-ihL/view?usp=sharingSupported By:Cancer Research And Statistic FoundationScientific Partners:AstraZenecaEvent Managed By:Horizon Conference ManagementFor more event updates, connect with us on:https://www.facebook.com/HorizonConferenceManagementhttps://www.linkedin.com/company/hcmpl/https://www.instagram.com/horizonconferencehttps://www.twitter.com/event_hcmplContact Us:Phone: +91 9820961667E-mail: email@example.comWebsite: www.hcmpl.comCopyright © 2021Horizon Conference Management Pvt. Ltd.All rights reserved.
Cleveland Clinic researchers have discovered, for the first time, that molecules in the gut related to what men eat are associated with aggressive prostate cancer. This suggests that changes in a man’s diet could help reduce his risk.
Early detection of breast and prostate cancer risk based on routine check-up data using machine learning and survival analysis – Dan Coster – MLCSB – Poster – ISMB/ECCB 2021
Translational Bridge SymposiumNovember 12, 2021Sarki A. Abdulkadir, MD, PhD Vice Chair for Research, Department of Urology John T. Grayhack, MD, Professor of Urological Research Professor of Urology and PathologyNorthwestern University Feinberg School of Medicine
Brian T. Helfand, MD, PhD, discusses the efficacy of next generation imaging options for localization of recurrent prostate cancer.